adplus-dvertising
Connect with us

Business

Did you get the AstraZeneca vaccine? Here's what you need to know – Vancouver Sun

Published

 on


Here’s a primer that breaks down why B.C. is halting the use of the AstraZeneca vaccine in younger people, but at the same time accelerating the vaccination of other age groups using this vaccine

Article content

On Monday, B.C. announced it was suspending the use of the AstraZeneca vaccine in people 55 and younger due to concerns over a “very rare” blood clot condition.

Here’s a primer that breaks down why B.C. is halting the use of the AstraZeneca vaccine in younger people, but at the same time accelerating the vaccination of other age groups using this vaccine.

Q: I got the AstraZeneca vaccine. What should I do?

A: If it has been more than 20 days since you received your AstraZeneca vaccine, you don’t need to worry.

If it has been less than 20 days, monitor yourself for symptoms and if you develop the following symptoms starting four to 20 days after receiving your shot, go to the nearest emergency department:

  • Severe headache that does not go away
  • Seizure
  • Difficulty moving parts of your body
  • Blurry vision that does not go away
  • Difficulty speaking
  • Shortness of breath
  • Chest pain
  • Severe abdominal pain
  • New severe swelling, pain, or colour change of an arm or a leg
  • Abnormal bruising, reddish or purple spots or blood blisters under the skin, or bleeding beyond the site of vaccination.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

For more information, visit the B.C. Centre for Disease Control vaccine information page.

If you have side effects such as pain, redness, itchiness or swelling at the injection site; swollen lymph nodes under the arm pit; tiredness or headache; fever and chills; muscle and joint soreness; nausea and vomiting — these are common symptoms that could surface a day or two after getting a COVID-19 vaccine. These symptoms should go away on their own.

Q: Why is B.C. stopping the use of the AstraZeneca vaccine for some people?

A: B.C. suspended the use of the AstraZeneca vaccine in people 55 and younger on Monday, acting on a recommendation from Canada’s National Advisory Committee on Immunization (NACI).

This comes amid new data from Europe that suggests the risk of blood clots is now potentially as high as one in 100,000 compared to the one in one million risk previously believed.

Called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT), these rare events have happened primarily among women under the age of 55, with a mortality rate of 40 per cent, although experts say that risk will be reduced if the condition is spotted and treated early.

There has been fewer than 30 cases identified around the world, primarily in Europe.

There has been no reports of blood clot incidents in people who have received the AstraZeneca vaccine in B.C. or in Canada.

In the meantime, Health Canada has asked the drug maker to conduct a study on the risks and benefits of the vaccine across multiple age groups. NACI has recommended the shot be suspended for younger groups pending the outcome of the review.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Q: Who has received the AstraZeneca shot in B. C.? 

A: In early March, B.C. said it will use around 68,000 doses of the vaccine to curb outbreaks and at high-risk workplaces, such as food processing, agriculture and large industrial camps.

The province then announced it planned to give priority to more than 300,000 front-line essential workers, including first responders, teachers, grocery store workers, and child care workers starting April. It is unclear how many of those workers can expect to get their shots.

Q: What’s the deal with the negative news surrounding AstraZeneca? 

A: The AstraZeneca vaccine was approved in Canada for adults on Feb. 26 under the brand names AstraZeneca COVID-19 Vaccine and COVISHIELD Vaccine. 

From the start, it had to fight against a perception it’s a lower-tier drug because of lower efficacy results than its competitors. Trials showed the vaccine was 62 per cent effective against COVID-19 infections, but entirely prevented COVID-19 related hospitalizations and deaths.

Then there was confusion about whether the AstraZeneca vaccine was effective for seniors. NACI initially withheld its recommendation on the use of the vaccine for seniors, but later reversed its decision, citing new real-world evidence from the U.K. that showed the vaccine was effective. 

In mid-March, European health authorities suspended use of the vaccine following reports of blood clots from people who have received the vaccine. Canadian health officials assured the public the vaccine is safe, as the very small number of people who experienced blood clots isn’t out of step with the normal rate of blood clots in the general population.

Advertisement

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

On March 24, Health Canada revised its label for the AstraZeneca vaccine to add information about the “very rare reports of blood clots associated with low levels of blood platelets.” It says the shot remains safe and the benefits of getting the vaccine outweigh the risks.

On March 29, NACI recommended against the use of the vaccine in people age 55 and younger. B.C. and other provinces suspended its use for this demographic.

Q: Is AstraZeneca safe? 

A: Health authorities maintain the vaccine is safe and effective.

On Tuesday, the provincial government announced it is moving up vaccine availability for people in the Lower Mainland ages 55 to 65. Starting Wednesday, eligible people will be able to call one of 150 pharmacies to make an appointment to receive an AstraZeneca shot. 

“We know from the millions of doses used worldwide, and especially in the U.K., it is highly effective and the benefits to those over age 55 far outweigh the very real risks of getting COVID-19,” said Dr. Bonnie Henry. “I encourage everyone in the Lower Mainland who is between 55 and 65 years of age to receive their safe and effective COVID-19 vaccine today.”

Q: Is this going to delay the vaccination schedule for younger people?

A: On Monday, B.C. Premier John Horgan said suspension of use of AstraZeneca among those 55 and younger does not impact the vaccination schedule in the age-based vaccination program.

Pfizer and BioNTech plans to move up delivery of five million doses of their mRNA vaccine to Canada in June. The first shipments of Johnson & Johnson’s single-dose vaccine are set to arrive at the end of April. It is not yet known how many doses are in the first shipment nor how many of those doses will be allocated to B.C.

chchan@postmedia.com

twitter.com/cherylchan

— with files from Postmedia News and Canadian Press

Comments

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending